During a Community Case Forum event in partnership with the Texas Society of Clinical Oncology, Natalie Vokes, MD, discussed ...

Pancreatic cancer is renowned for its aggressive nature and dismal prognosis, with the majority of patients diagnosed at an advanced stage. The prognosis for patients with pancreatic cancer can be ...

VITRAKVI has strong market potential as a first-in-class TRK inhibitor for patients with NTRK gene fusion-positive cancers, regardless of tumor type. The growing adoption of precision oncology ...

DelveInsight's "VITRAKVI Market Size, Forecast, and Market Insight Report" highlights the details around VITRAKVI, a TRK, ...

During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for ...

As biomarker testing and the demand for tumor-agnostic therapies rise, ROZLYTREK can potentially target a specialized yet valuable market segment. While competition from other TRK inhibitors ...

Genetic testing helps determine whether any specific gene mutations are driving your lung cancer. Once a mutation is identified, a doctor may modify your cancer treatment to target it. A genetic ...

If your non-small cell lung cancer (NSCLC) involves a gene mutation, you may receive a targeted therapy. These medications address specific gene mutations more effectively than standard cancer ...

These biomarkers are EGFR, ALK, ROS1, BRAF, KRAS, MET, HER2, RET, and NTRK. Your doctor will choose treatments that are most likely to work based on the mutations they find in your NGS test results.

NTRK fusion, in solid tumours. “In years past, we would have had to give chemotherapy drugs, big, toxic, strong, nasty chemotherapy drugs that make your hair fall out and give you low blood ...